Breaking News

ShangPharma Opens Pilot Plant Facility

ShangPharma Corp. began operations on the initial phase of production at its new pharmaceutical development and cGMP manufacturing facility in Fengxian, China.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ShangPharma Corp. began operations on the initial phase of production at its new pharmaceutical development and cGMP manufacturing facility in Fengxian, China. The facility, a wholly owned subsidiary of ShangPharma, will operate as China Gateway Pharmaceutical Development Co. Ltd., and will allow the company to expand its service offering to include process R&D, formulation R&D, analytical method development and validation, and cGMP manufacturing of intermediates and APIs. With the ne...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters